CLIFFS NATURAL RESOURCES INC. NOTES REVISED GLASS LEWIS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
CLIFFS NATURAL RESOURCES INC. NOTES REVISED GLASS LEWIS RECOMMENDATION

      Glass Lewis Recommends Shareholders Vote  On WHITE Proxy Card For ALL Seven Cliffs Nominees

All Three Proxy Advisory Firms Have Consistently Recommended Cliffs  Retain Majority of the Board

CLEVELAND, July 24, 2014 (GLOBE NEWSWIRE) --   Cliffs Natural Resources Inc. (NYSE: CLF ) today announced that Glass Lewis & Co ("Glass Lewis"), a leading proxy advisory firm, has issued a revised recommendation and now recommends that shareholders vote " FOR ALL " of Cliffs' director nominees on the WHITE proxy card in connection with the Company's 2014 Annual Meeting of Shareholders to be held on Tuesday, July 29, 2014.

Cliffs today issued the following statement in response to this important development:

We are pleased that Glass Lewis has recommended that shareholders vote on Cliffs' WHITE proxy card and that Glass Lewis recognizes "that voting on the Dissident's proxy card carries the risk that the Dissident might use cumulative voting in its favor to potentially gain a majority of the Company's board seats, even if that's not the result that shareholders are perhaps generally seeking." 1

In its July 23, 2014 report, Glass Lewis also noted that "Given our noted concerns regarding the Dissident's plan for the Company, and absent further details and refinement of such plan on the part of the Dissident, we remain reticent in making a recommendation to support the Dissident's entire slate. Considering that the board has now specifically identified two additional incumbent directors who are willing to step down, and the potential adverse impact that cumulative voting could have on this election as well as our continued concerns regarding certain aspects of the Dissident's plan for the Company, we believe that shareholders would be best served voting on the Company's revised WHITE proxy card." 1

All three proxy advisory firms, Glass Lewis, Institutional Shareholder Services ("ISS") and Egan-Jones have recommended that Cliffs retain a majority of the Board.  We further note that ISS's support of the gold proxy card is inconsistent with its underlying recommendation, as they fail to recognize that if shareholders follow the ISS recommendation and vote the gold card, Casablanca will be able to use cumulative voting to secure a majority of the Board. 

As Glass Lewis and Egan-Jones have explained, by voting the WHITE proxy card, Cliffs shareholders will elect a Board that includes shareholder representation by Casablanca Capital, but that also retains a majority of the directors Cliffs believes have the necessary industry and commodity cycle experience to lead the Company in the current iron ore and met coal pricing environment and emerge from the downturn as a stronger company.

As previously announced, Cliffs offered to include four Casablanca nominees on our WHITE proxy card; however, Casablanca has rejected our request that the Casablanca nominees consent to be included on our  WHITE  card, which clearly indicates Casablanca's sole objective is to take a majority of the Board.  If shareholders vote using the gold proxy card, NO votes can be cumulated to any of the current members of the Board and it is almost certain that Casablanca will be able to use Cliffs' cumulative voting provision to elect all six of their nominees, providing Casablanca with a majority of the Board and enabling the hedge fund to enact what we believe is a value-destructive plan, including a "fire sale" of Cliffs' assets at the bottom of the commodity cycle. 

Cliffs urges shareholders to follow the recommendations of Glass Lewis and Egan-Jones and vote on Cliffs' revised WHITE proxy card " FOR ALL " seven nominees: Gary B. Halverson, Mark E. Gaumond, Susan M. Green, Janice K. Henry, James F. Kirsch, Richard K. Riederer and Timothy W. Sullivan.  If shareholders vote on the gold card, we believe Casablanca will be able to elect all six of its nominees, providing Casablanca with a majority of the Board.

If shareholders have any questions on cumulative voting or need assistance voting, please contact D.F. King & Co., Inc., which is assisting Cliffs in connection with this year's Annual Meeting, at (800) 487-4870.

J.P. Morgan and Bank of America Merrill Lynch are acting as financial advisors to the Company and Wachtell, Lipton, Rosen & Katz and Jones Day are acting as legal counsel.

About Cliffs Natural Resources Inc.

Cliffs Natural Resources Inc. is an international mining and natural resources company. The Company is a major global iron ore producer and a significant producer of high-and low-volatile metallurgical coal. Cliffs' strategy is to continually achieve greater scale and diversification in the mining industry through a focus on serving the world's largest and fastest growing steel markets. Driven by the core values of social, environmental and capital stewardship, Cliffs associates across the globe endeavor to provide all stakeholders operating and financial transparency.

The Company is organized through a global commercial group responsible for sales and delivery of Cliffs' products and a global operations group responsible for the production of the minerals the Company markets. Cliffs operates iron ore and coal mines in North America and an iron ore mining complex in Western Australia.

News releases and other information on the Company are available on the Internet at: http://www.cliffsnaturalresources.com

Follow Cliffs on Twitter at: http://twitter.com/CliffsNR .

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. Although the Company believes that its forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties relating to Cliffs' operations and business environment that are difficult to predict and may be beyond Cliffs' control. Such uncertainties and factors may cause actual results to differ materially from those expressed or implied by forward-looking statements for a variety of reasons including without limitation: trends affecting our financial condition, results of operations or future prospects, particularly the continued volatility of iron ore and coal prices; our actual levels of capital spending; uncertainty or weaknesses in global economic conditions, including downward pressure on prices, reduced market demand and any slowing of the economic growth rate in China; a currently pending proxy contest and any other actions of activist shareholders; our ability to successfully integrate acquired companies into our operations and achieve post-acquisition synergies, including without limitation, Cliffs Quebec Iron Mining Limited (formerly Consolidated Thompson Iron Mining Limited); our ability to successfully identify and consummate any strategic investments and complete planned divestitures; the outcome of any contractual disputes with our customers, joint venture partners or significant energy, material or service providers or any other litigation or arbitration; the ability of our customers and joint venture partners to meet their obligations to us on a timely basis or at all; our ability to reach agreement with our iron ore customers regarding any modifications to sales contract provisions; the impact of price-adjustment factors on our sales contracts; changes in sales volume or mix; our actual economic iron ore and coal reserves or reductions in current mineral estimates, including whether any mineralized material qualifies as a reserve; the impact of our customers using other methods to produce steel or reducing their steel production; events or circumstances that could impair or adversely impact the viability of a mine and the carrying value of associated assets; the results of prefeasibility and feasibility studies in relation to projects; impacts of existing and increasing governmental regulation and related costs and liabilities, including failure to receive or maintain required operating and environmental permits, approvals, modifications or other authorization of, or from, any governmental or regulatory entity and costs related to implementing improvements to ensure compliance with regulatory changes; our ability to  cost-effectively achieve planned production rates or levels; uncertainties associated with natural disasters, weather conditions, unanticipated geological conditions, supply or price of energy, equipment failures and other unexpected events; adverse changes in currency values, currency exchange rates, interest rates and tax laws; availability of capital and our ability to maintain adequate liquidity and successfully implement our financing plans; our ability to maintain appropriate relations with unions and employees and enter into or renew collective bargaining agreements on satisfactory terms; risks related to international operations; availability of capital equipment and component parts; the potential existence of significant deficiencies or material weakness in our internal control over financial reporting; problems or uncertainties with productivity, tons mined, transportation, mine-closure obligations, environmental liabilities, employee-benefit costs and other risks of the mining industry; and other factors and risks that are set forth in the Company's most recently filed reports with the U.S. Securities and Exchange Commission (the "SEC"). The information contained herein speaks as of the date of this release and may be superseded by subsequent events. Except as may be required by applicable securities laws, we do not undertake any obligation to revise or update any forward-looking statements contained in this release.

Important Additional Information

Cliffs, its directors and certain of its executive officers are deemed to be participants in the solicitation of proxies from Cliffs' shareholders in connection with the matters to be considered at Cliffs' 2014 Annual Meeting. Cliffs filed a definitive proxy statement with the SEC on June 10, 2014 in connection with any such solicitation of proxies from Cliffs' shareholders. CLIFFS' SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT AND ACCOMPANYING WHITE PROXY CARD AS THEY CONTAIN IMPORTANT INFORMATION. Information regarding the ownership of Cliffs' directors and executive officers in Cliffs' shares, restricted shares and options is included in their SEC filings on Forms 3, 4 and 5. More detailed information regarding the identity of participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement and other materials to be filed with the SEC in connection with Cliffs' 2014 Annual Meeting. Information can also be found in Cliffs' Annual Report on Form 10-K for the year ended Dec. 31, 2013, filed with the SEC on Feb. 14, 2014, as amended and filed with the SEC on April 30, 2014, and Cliffs' definitive proxy statement on Schedule 14A, filed with the SEC on June 10, 2014. Shareholders will be able to obtain the proxy statement, any amendments or supplements to the definitive proxy statement and other documents filed by Cliffs with the SEC for no charge at the SEC's website at www.sec.gov . Copies will also be available at no charge at Cliffs' website at www.cliffsnr.com or by contacting James Graham, Vice President, Chief Legal Officer & Secretary at (216) 694-5504. Shareholders may also contact D.F. King & Co., Inc., Cliffs' proxy solicitor, toll-free at (800) 487-4870 or by email at cliffs@dfking.com .

Investors Jessica Moran Director, Investor Relations (216) 694-6532 Jordan Kovler D.F. King & Co., Inc. (212) 493-6990 Media Patricia Persico Director, Global Communications (216) 694-5316 Joele Frank, Meaghan Repko or Andrea Rose Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 255

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 266

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 113

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 115

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 59

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Scent Dispensing Solution for Hunting Enthusiasts

Updated Category News Views 168

Introducing a Game-Changing Scent Dispensing System In the world of hunting, attracting game animals can often be a challenge. A new invention, designed specifically for this purpose, promises to make the process much simpler and more efficient. The inventor of this innovative scent dispensing system, THE DRAG LINE PRO, envisioned a better way to utilize a scent drag...

Continue Reading
Corby Spirit and Wine Limited Reports Impressive Fiscal Results

Updated Category News Views 295

Corby Spirit and Wine Limited Announces Strong Fiscal Performance Corby Spirit and Wine Limited, renowned for its position as a leading Canadian manufacturer, marketer, and importer of spirits, has recently unveiled impressive results for its fourth quarter and full-year fiscal 2025. The company demonstrated significant growth in revenue, achieving total revenues of...

Continue Reading
Sezzle Faces Setback as Short-Seller Targets Its Practices

Updated Category News Views 113

Sezzle's Stock Takes a Dramatic Hit Recently, the buy now, pay later (BNPL) provider Sezzle experienced a significant decrease in its stock value. Reports indicate that shares fell over 28.6% in early trading after Hindenburg Research disclosed a short position against the company due to concerns surrounding risky lending practices. Understanding the Short-Selling...

Continue Reading
Exploring the Growth of $1000 in Marsh & McLennan Cos Today

Updated Category News Views 116

Understanding Long-Term Investment in Marsh & McLennan Marsh & McLennan Cos (NYSE: MMC) has established itself as a financial powerhouse, outperforming the market consistently over the past two decades. Investors have experienced an impressive annualized return of 13.31%, showcasing the benefits of long-term investment strategies. The Value of Persistence in Investing...

Continue Reading
Discover Toll Brothers' Latest Luxury Homes at Overbrook Estates

Updated Category News Views 671

Introducing Overbrook Estates by Toll Brothers Toll Brothers, Inc. (NYSE:TOL), a renowned name in luxury homebuilding, excitedly unveils its newest community: Overbrook Estates. This anticipated project is set to grace the Huntersville area, offering homebuyers elegant living in a master-planned environment. Positioned conveniently off Highway 77, this prime location sets...

Continue Reading